Somatically acquired uniparental disomy (UPD) has been recognized as a common mechanism of mutation amplification in cancer. Somatic heterozygous mutations can become homozygous if the chromosomal arm harboring the mutation undergoes mitotic recombination and two chromosomes carrying the mutation segregate into the same daughter cell. As a result, UPD occurs, accompanied by loss of heterozygosity from the recombination breakpoint to the telomere of the affected chromosomal arm. UPD of chromosome 9p is a frequent event in myeloproliferative neoplasms and was found to be associated with the oncogenic V617F mutation of the JAK2 gene. The mutation identified in this study is shown in bold, other two mutations described in literature are also shown. 5 (d) Two possible mechanisms of clonal outgrowthFeither FANCM R658X is the driver or other somatic mutation that occurred on the same chromosome, drives the clonality. White star, putative somatic mutation; black star, FANCM mutation; Mb, mega base pairs.
A number of other UPDs were shown to amplify heterozygous mutations in genes such as MPL, CBL and EZH2 in myeloid malignancies. [2] [3] [4] We recently identified a patient with the diagnosis of polycythemia vera that carried UPD on the long arm of chromosome 14 (Figure 1a) . We hypothesized that a homozygous somatic mutation might be present in the chromosomal region affected by UPD. In an attempt to identify the mutation, we employed next-generation sequencing of all the exons of the patient. Granulocyte genomic DNA was fragmented to an average of 150 bp and the synthesis of a fragment library was performed using the standard manufacturer's protocol (Illumina, San Diego, CA, USA). We enriched for exonic sequences using the SureSelect Human All Exon kit (Agilent, Santa Clara, CA, USA) and performed a 51-bp paired-end sequencing with the HiSeq2000 system (Illumina). After reference alignment of 178 million reads, variations from the genomic reference were identified and filtered based on the physical position of the 14qUPD and allelic frequency consistent with homozygosity. We further removed known single-nucleotide polymorphisms (SNPs), synonymous variants and non-coding SNPs. One of the variants validated by Sanger sequencing was a homozygous nonsense mutation in the FANCM gene, truncating the protein at codon 658 (R658X). We did not find R658X in any of the public databases (dbSNP, 1000 Genomes Project, OMIM, Fanconi Anemia Mutation Database). The analysis of buccal mucosa cells revealed that the patient was a germline heterozygous carrier of the FANCM R658X mutation (Figure 1b ). Another nonsense mutation was identified in a family with Fanconi anemia of the complementation group M, where the affected pedigree members carried two mutated alleles (S724X and a 2.5 kb deletion affecting exon 15, Figure 1c) . 5 As the same study also showed that the S724X nonsense mutation is a loss-offunction variant, we conclude that the more severe truncation caused by the R658X mutation is also loss-of-function. The R658X mutation is the third FANCM mutation reported to date.
Fanconi anemia is a heterogeneous hereditary blood disorder characterized by early onset anemia, cancer predisposition and various congenital abnormalities. The male polycythemia vera patient who carried the R658X mutation of FANCM was diagnosed in December 1993 at age of 44 as polycythemia vera with a hematocrit of 66.6% and serum erythropoietin levels below detection limit. The patient was positive for the JAK2-V617F mutation and required regular phlebotomies. In September 2000, the patient presented with increased leukocyte count (17.5 Â 10 9 /l). Between September and November 2003, the patient was in a plateau phase without a need of phlebotomies. In January 2004, the patient presented first time with anemia and 1% of blasts in the peripheral blood. The patient required transfusions since January 2005. We sampled the patient in September 2006 for the karyotype analysis, using the SNP 6.0 mapping arrays (Affymetrix, Santa Clara, CA, USA). The patient exhibited 9pUPD with high JAK2-V617F mutation burden and 14qUPD, but no other chromosomal aberrations. At this sampling date, the patient was anemic (hemoglobin 6.8 g/l) with 2% blasts in peripheral blood, had a leukocyte count of 25.2 Â 10 9 /l and a marked thrombocytosis (platelet count 3753 Â 10 The clinical history of the patient suggests that the patient first acquired the JAK2-V617F mutation causing the onset of the polycythemia vera phenotype. Anemia in this patient was most likely caused by a subsequent clonal selection of cells that acquired homozygosity for FANCM R658X due to mitotic recombination on chromosome 14q. The resulting clone homozygous for two detrimental mutations (JAK2-V617F and FANCM R658X) caused the transition of polycythemia to anemia, marked thrombocytosis and leukocytosis. It is possible that the leukemic transformation in this patient was a consequence of the homozygosity to the FANCM mutation, as Fanconi anemia patients often develop acute leukemia. At this point, we do not know if homozygosity for R658X was driving the clonal selection. It is possible that a somatic mutation on 14q was the driver and the FANCM R658X mutation coacquired homozygosity with the yet unknown driver mutation (Figure 1d) .
In a recently published high-resolution SNP microarray study, we detected 147 UPD events affecting 12 different chromosomal arms in 321 chronic phase myeloproliferative neoplasms patients (9pUPD was present in about 37% of myeloproliferative neoplasms cases). 6 All these UPD events could switch rare deleterious germline variants to homozygosity and influence the clinical phenotype of patients. We performed exome sequencing in 11 patients with 9pUPD. In average, we detect 636 nonsynonymous variants per patient that are not in public databases (dbSNP, 1000 Genomes Project). The 9pUPD regions of these 11 cases contained between 0-7 non-synonymous variants per Letters to the Editor patient (excluding JAK2-V617F). At this point, it is challenging to predict the influence of these non-synonymous variants on the clinical phenotype of each individual patient. However, using the PolyPhen-2 algorithm (http://genetics.bwh.harvard.edu/ pph2), one third of these non-synonymous variants are predicted to damage the protein function (data not shown). Therefore, any myeloproliferative neoplasms patient with loss of heterozygosity has the potential to embark on a unique clinical course driven by the distinct set of rare variants each patient carries within the loss of heterozygosity region.
In general, somatically acquired UPDs can influence phenotypic effect of germline variants and epigenetic marks (Figure 2) . UPDs can result in homozygosity of rare deleterious germline mutations (Figure 2a ) that have no phenotypic effect when heterozygous. In addition, UPDs may either increase or reduce the expression of imprinted genes located on the affected chromosomal arm (Figure 2b) . Although the prevailing opinion in cancer genetics is that somatic mutations are contributing to disease initiation and progression, our study demonstrates that a unique interplay of germline variants with somatic aberrations may influence disease pathogenesis in each individual case.
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MicroRNAs (miRNAs) are a class of small non-coding singlestranded RNAs of B22 nucleotides in length that regulate protein levels by binding to either partially or complete complementary sites in messenger RNAs (mRNAs), leading to translational repression or transcript degradation, respectively. MiRNAs have a role in critical biological processes including cellular growth and differentiation. Recent studies showed that miRNAs have an important role in the pathogenesis of multiple myeloma (MM) and that miRNA signatures are associated with different cytogenetic subtypes. Unsupervised analyses of miRNA expression in MM identified unique clusters, which were not associated with chromosomal abnormalities, while supervised analysis showed a specific miRNA expression pattern for MM subgroups. [1] [2] [3] We have investigated the expression level of 365 miRNAs in sorted bone marrow (BM) plasma cells of 45 newly diagnosed MM patients enrolled in the HOVON-65/GMMG-HD4 trial (Supplementary Table S1 ) and 4 healthy individuals (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/, accession number GSE16558). 1 We addressed the question whether MM patients could be classified based on miRNA expression patterns. MiRNA expression data were linked to gene expression data to gain more insight into candidate miRNA target genes.
Finally, a possible association of miRNA expression with response to therapy, that is, complete response (CR), nearly CR (nCR), progression-free survival (PFS) and overall survival (OS), was evaluated.
Unsupervised hierarchical cluster analysis based on miRNA expression showed that normal BM samples clustered distinctly from MM samples (Figure 1) . A total of 44 MM samples were grouped in four distinct clusters and one MM sample was not included in any MM cluster. The robustness indices per cluster are shown in Supplementary Table S2 . To determine the miRNA expression signatures of the four MM and one normal BM cluster, each cluster was compared with the remaining clusters using the Mann-Whitney U-test with a false discovery rate (FDR)o0.05 (Partek Genomics Suite 6.4 software). The top 10 significant distinctive miRNAs for the four MM clusters and normal BM cluster are shown in Tables 1 and 2 , respectively. The complete list of differentially expressed miRNAs (FDRo0.05) characterizing the four MM clusters and normal BM cluster is shown in Supplementary Tables S3 and S4 , respectively. MM cluster 1 (n ¼ 8) was characterized by upregulation of 17 miRNAs, including miRNA-130a, -424 and -622; MM cluster 2 (n ¼ 9) by upregulation of miRNA-576 and -106b; MM cluster 3 (n ¼ 4) by upregulation of 23 miRNAs, including miRNA-372 and -200a, and downregulation of miRNA-146b; and MM cluster 4 (n ¼ 23) was characterized by downregulation of 60 miRNAs. An interesting observation is the
